- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 213/40 - Acylated substituent nitrogen atom
Patent holdings for IPC class C07D 213/40
Total number of patents in this class: 602
10-year publication summary
|
53
|
52
|
58
|
51
|
41
|
36
|
34
|
34
|
32
|
8
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| H. Lundbeck A/S | 1252 |
12 |
| The Regents of the University of California | 18943 |
9 |
| Genentech, Inc. | 3742 |
9 |
| Givaudan SA | 1760 |
9 |
| Bristol-myers Squibb Company | 5080 |
8 |
| AstraZeneca AB | 3042 |
8 |
| The General Hospital Corporation | 4517 |
8 |
| The Scripps Research Institute | 1364 |
8 |
| Corteva Agriscience LLC | 2494 |
8 |
| Boehringer Ingelheim International GmbH | 4629 |
7 |
| Amgen Inc. | 3779 |
7 |
| Curis, Inc. | 130 |
7 |
| Ono Pharmaceutical Co., Ltd. | 454 |
7 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
7 |
| F. Hoffmann-La Roche AG | 7958 |
6 |
| Massachusetts Institute of Technology | 9795 |
6 |
| The Broad Institute, Inc. | 1584 |
6 |
| Gilead Sciences, Inc. | 1879 |
6 |
| Glenmark Pharmaceuticals S.A. | 124 |
6 |
| Grünenthal GmbH | 625 |
6 |
| Other owners | 452 |